Please use this identifier to cite or link to this item:
|Title:||Pharmacology of celiprolol.||Austin Authors:||Louis, William J ;Drummer, Olaf H;Tung, L H||Affiliation:||University of Melbourne, Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australia||Issue Date:||1-Jan-1991||Publication information:||Cardiovascular Drugs and Therapy / Sponsored By the International Society of Cardiovascular Pharmacotherapy; 4 Suppl 6(): 1281-5||Abstract:||The pharmacology of celiprolol and its relationship to some other beta-adrenoceptor antagonists is described. Celiprolol is a potent beta blocker on beta 1-adrenoceptors and exhibits cardioselectivity both in vitro and in vivo in the pithed rat, but shows no significant in vitro alpha 1-blocking action. Celiprolol differs from atenolol in that it has an intrinsic sympathomimetic activity (ISA) for beta 1-adrenoceptors, which is reflected in its relative lack of negative inotropic effects in humans. In the pithed rat, celiprolol's ISA was demonstrated at much lower doses than for pindolol, even though pindolol has a similar potency to celiprolol in antagonizing the heart rate effects of isoproterenol. It was completely blocked by propranolol, indicating that celiprolol behaves like a partial agonist for beta 1-adrenoceptors, whereas the ISA developed by pindolol was only partially blocked by propranolol. These data suggest a different mechanism for the development of ISA between celiprolol and pindolol.||Gov't Doc #:||1672604||URI:||http://ahro.austin.org.au/austinjspui/handle/1/10160||URL:||https://pubmed.ncbi.nlm.nih.gov/1672604||Type:||Journal Article||Subjects:||Adrenergic beta-Agonists
Heart Atria.drug effects
In Vitro Techniques
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 2, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.